PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY DRUG CLASS Market segmentation by drug class Comparison by drug class Antimetabolites - Market size and forecast 2018-2023 Plant derivatives - Market size and forecast 2018-2023 Cytotoxic antibiotics - Market size and forecast 2018-2023 Alkylating agents - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by drug class PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Market trends PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb Co. Eli Lilly and Co. Johnson & Johnson Services Inc. Novartis AG Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Combination therapy approvals Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Drug class - Market share 2018-2023 (%) Exhibit 19: Comparison by drug class Exhibit 20: Antimetabolites - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Antimetabolites - Year-over-year growth 2019-2023 (%) Exhibit 22: Plant derivatives - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Plant derivatives - Year-over-year growth 2019-2023 (%) Exhibit 24: Cytotoxic antibiotics - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Cytotoxic antibiotics - Year-over-year growth 2019-2023 (%) Exhibit 26: Alkylating agents - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Alkylating agents - Year-over-year growth 2019-2023 (%) Exhibit 28: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 29: Others - Year-over-year growth 2019-2023 (%) Exhibit 30: Market opportunity by drug class Exhibit 31: Customer landscape Exhibit 32: Market share by geography 2018-2023 (%) Exhibit 33: Geographic comparison Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 35: North America - Year-over-year growth 2019-2023 (%) Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Approvals of chemotherapeutics Exhibit 45: Side-effects of chemotherapy drugs Exhibit 46: Impact of drivers and challenges Exhibit 47: Combination therapies under late-stage clinical trials Exhibit 48: Repurposed chemotherapy agents Exhibit 49: Antibody drug conjugates undergoing clinical trials Exhibit 50: Vendor landscape Exhibit 51: Landscape disruption Exhibit 52: Vendors covered Exhibit 53: Vendor classification Exhibit 54: Market positioning of vendors Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview Exhibit 56: Bristol-Myers Squibb Co. - Business segments Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus Exhibit 59: Bristol-Myers Squibb Co. - Key offerings Exhibit 60: Eli Lilly and Co. - Vendor overview Exhibit 61: Eli Lilly and Co. - Business segments Exhibit 62: Eli Lilly and Co. - Organizational developments Exhibit 63: Eli Lilly and Co. - Geographic focus Exhibit 64: Eli Lilly and Co. - Segment focus Exhibit 65: Eli Lilly and Co. - Key offerings Exhibit 66: Johnson & Johnson Services Inc. - Vendor overview Exhibit 67: Johnson & Johnson Services Inc. - Business segments Exhibit 68: Johnson & Johnson Services Inc. - Organizational developments Exhibit 69: Johnson & Johnson Services Inc. - Geographic focus Exhibit 70: Johnson & Johnson Services Inc. - Segment focus Exhibit 71: Johnson & Johnson Services Inc. - Key offerings Exhibit 72: Novartis AG - Vendor overview Exhibit 73: Novartis AG - Business segments Exhibit 74: Novartis AG - Organizational developments Exhibit 75: Novartis AG - Geographic focus Exhibit 76: Novartis AG - Segment focus Exhibit 77: Novartis AG - Key offerings Exhibit 78: Pfizer Inc. - Vendor overview Exhibit 79: Pfizer Inc. - Business segments Exhibit 80: Pfizer Inc. - Organizational developments Exhibit 81: Pfizer Inc. - Geographic focus Exhibit 82: Pfizer Inc. - Segment focus Exhibit 83: Pfizer Inc. - Key offerings Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of market positioning of vendors

Bristol-Myers Squibb Co. Eli Lilly and Co. Johnson & Johnson Services Inc. Novartis AG Pfizer Inc.